p300 Lentiviral Activation Particles (h): sc-400055-LAC

Human EP300 encodes p300, a multifunctional lysine acetyltransferase and transcriptional coactivator that integrates signals from diverse transcription factors to regulate chromatin accessibility and gene expression programs. p300 acetylates histones and non-histone substrates and participates in core pathways controlling cell cycle progression, DNA damage responses, differentiation, metabolism, and immune signaling, often through coordination with CREB, p53, NF-κB, and nuclear receptors. Through its role in enhancer and promoter regulation, p300 helps shape lineage-specific transcription and stress-adaptive responses. Dysregulation of EP300/p300 activity or expression is implicated in oncogenic transcriptional states and other disorders involving altered chromatin regulation and transcriptional control.

p300 Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient EP300 upregulation across a broader range of human cell types.

p300 Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the EP300 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous p300 expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native EP300 genomic locus and regulatory architecture.

The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.